Black Diamond advances in brain cancer
Silevertinib trial will evaluate patients with unmethylated MGMT and EGFRvIII mutations.
Black Diamond joins ArriVent in the PACC pack
BDTX-1535 takes aim at PACC mutations and Tagrisso resistance.
The month ahead: September’s upcoming events
It’s back to school for biotech, with a packed conference schedule.
Black Diamond picks its lung cancer battle
The biotech gives up on the exon 20 market, and says Tagrisso’s initial setting is no longer meaningful in the west.
Triple meeting 2023 preview – firsts for Amgen and Novartis
But Repare and Black Diamond still have rebuilding to do.
Lung cancer switch does the job for Black Diamond
First data with the biotech’s new EGFR project prompts a 236% share price bump.
